

GREENWICH LIFESCIENCES

**Planned GLSI-100
(GP2 + GM-CSF)
Phase III Clinical Trial,
FLAMINGO-01**



**A Breakthrough Targeted
Immunotherapy to Prevent
Breast Cancer Recurrences**

NASDAQ: GLSI

Snehal Patel, CEO



**Greenwich
LifeSciences**



Safe Harbor Statement

This document is the property of Greenwich LifeSciences, Inc., (the “Company” or “Greenwich LifeSciences”). This document is non-directive in nature (contains no recommendations regarding financial actions related to the Company). This document is not to be copied or delivered to any other person or used for any other purpose without the prior consent of the Company.

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995.

These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements including, but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, intellectual property rights and the need for additional financing.

Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Except as required by law, the Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events.

The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Although every effort has been made to assure the accuracy of the statements in this presentation, we make no representation or warranty as to the accuracy or completeness of the statements in this presentation. Furthermore, we make forward-looking statements in this report about the Company’s plans, objectives, expectations, and intentions.

This presentation is not an offer to sell any securities of the Company and is not to be used in connection with any offer to sell or any inquiry about or evaluation of any securities of the Company. Any such sale, or opportunity, will be subject to appropriate documentation and due diligence.

GLSI-100 (GP2 + GM-CSF) Executive Summary



Flamingo-01 - Current Phase III Trial with Interim Analysis: 9 amino acid HER2/*neu* peptide + GM-CSF immunotherapy for breast cancer in HER2/*neu* positive patients following neoadjuvant, surgery, & adjuvant Herceptin or Kadcyra, led by Baylor & consortium of prominent networks - up to 180 sites in US & EU

- Conservative design of Phase III trial to reproduce Phase IIb results
- **Phase IIb Trial Results:** Randomized, multi-center (16 centers), placebo-controlled, substantial reduction in recurrence rate, peak immunity after 6 months, minimal to no side effects, no SAEs attributable to GP2, led by MD Anderson Cancer Center
- **Potential Opportunities to Expand Market:**
 - HER2/*neu* low patients with Herceptin - increase market from 25% to 75%
 - ✓ – Other HLA types – increase from 40-50% up to 80-100% of all patients
 - Combination with CD4/CD8 peptides and checkpoints
 - Other HER2/*neu* cancers
- **NASDAQ Ticker “GLSI”:** Raised \$60m since IPO


Recently granted Fast Track designation by FDA

First Year Share Price Performance After Presenting Key Phase IIb Data in 2020/2021


- Raised approximately \$36.5M from IPO & Follow-on in 2020
- Peak share prices and trading volume driven by data publications
- 30x or 2,940% return from intraday high on 12/9/20, possibly highest intraday return for a non-penny stock from prior day close
- Added to Russell 2000 twice: 2021 and 2024
- Management & Directors ownership (tightly held): 75-85%
- Low float - Locked up from IPO in Sept 2020 through Jan 2027 at BOD discretion



2021 American Association for Cancer Research (AACR) Immune Response Supports Mechanism of Action




2021 SABCS Baseline GP2 Immune Response May Predict Faster & Earlier Recurrence




5 Year Data Set of GP2 Phase IIb Trial is Complete

HER2 3+ (Positive) Patients who Completed the Primary Immunization Series (PIS)



ASCO 2021 – Systemic & Injection Site Reactions

Figure 2: Incidence of Maximum Severity Grade Adverse Events



The maximal severity grade for any AE, systemic and injection site reaction, for each patient was identified. There was no difference between the two treatment arms, as presented in Figure 2. The majority of events were of grade 1, mild severity. Two patients reported grade 4 AEs deemed unrelated to study medication. One GP2+GM-CSF patient experienced grade 4 hypoglycemia and recovered. A GM-CSF only patient was diagnosed with renal cell carcinoma, a second primary diagnosis, which was classified as grade 4.

No serious adverse events considered related to study medication were reported

ASCO 2021 – Incidence of Adverse Events

Tables 1 & 2: Incidence of Adverse Events

Table 1: Incidence of First Occurrence of Most Frequent Adverse Events

	HER2 3+		HER2 1-2+		Total	
Adverse Event	GP2 (n = 51) N (%)	Placebo (n = 50) N (%)	GP2 (n = 38) N (%)	Placebo (n = 41) N (%)	GP2 (n = 89) N (%)	Placebo (n = 91) N (%)
Injection site reaction	50 (98.0)	50 (100)	37 (97.4)	40 (97.6)	87 (97.8)	90 (98.9)
Fatigue	36 (70.6)	30 (60.0)	26 (68.4)	25 (61.0)	62 (69.7)	55 (60.4)
Headache	23 (45.1)	26 (52.0)	18 (47.4)	19 (46.3)	41 (46.1)	45 (49.5)
Myalgia	19 (37.3)	16 (32.0)	13 (34.2)	10 (24.4)	32 (36.0)	26 (28.6)
Bone pain	12 (23.5)	17 (34.0)	12 (31.6)	10 (24.4)	24 (27.0)	27 (29.7)
Arthralgia	18 (35.3)	19 (38.0)	5 (13.2)	7 (17.1)	23 (25.8)	26 (28.6)
Malaise	14 (27.5)	11 (22.0)	7 (18.4)	9 (22.0)	21 (23.6)	20 (22.0)
Chills	12 (23.5)	14 (28.0)	7 (18.4)	6 (14.6)	19 (21.3)	20 (22.0)
Back pain	13 (25.5)	9 (18.0)	7 (18.4)	6 (14.6)	20 (22.5)	15 (16.5)
Nausea	9 (17.6)	15 (30.0)	5 (13.2)	6 (14.6)	14 (15.7)	21 (23.1)
Fever	12 (23.5)	13 (26.0)	5 (13.2)	4 (9.8)	17 (19.1)	17 (18.7)
Dizziness	6 (11.8)	4 (8.0)	2 (5.3)	3 (7.3)	8 (9.0)	7 (7.7)

Table 2: Incidence of First Occurrence of Injection Site Reactions

	HER2 3+		HER2 1-2+		Total	
Adverse Event	GP2 (n = 51) N (%)	Placebo (n = 50) N (%)	GP2 (n = 38) N (%)	Placebo (n = 41) N (%)	GP2 (n = 89) N (%)	Placebo (n = 91) N (%)
Erythema	50 (98.0)	50 (100.0)	37 (97.4)	39 (95.1)	87 (97.8)	89 (97.8)
Pruritus	50 (98.0)	46 (92.0)	37 (97.4)	38 (92.7)	87 (97.8)	84 (92.3)
Induration	50 (98.0)	40 (80.0)	37 (97.4)	36 (87.8)	87 (97.8)	76 (83.5)
Pain	9 (17.6)	5 (10.0)	6 (15.8)	5 (12.2)	15 (16.9)	10 (11.0)
Warm	3 (5.9)	5 (10.0)	2 (5.3)	0 (0.0)	5 (5.6)	5 (5.5)
Bruising	1 (2.0)	4 (8.0)	2 (5.3)	0 (0.0)	3 (3.4)	4 (4.4)
Urticaria	1 (2.0)	3 (6.0)	1 (2.6)	1 (2.4)	2 (2.2)	4 (4.4)
Rash	1 (2.0)	2 (4.0)	1 (2.6)	0 (0.0)	2 (2.2)	2 (2.2)
Blanching	2 (3.9)	1 (2.0)	0 (0.0)	0 (0.0)	2 (2.2)	1 (1.1)
Burning	1 (2.0)	1 (2.0)	0 (0.0)	0 (0.0)	1 (1.1)	1 (1.1)
Myalgia	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)	1 (1.1)	0 (0.0)
Tingling	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)

The first occurrence of frequently reported AEs is tabulated in Table 1. The most common AE was injection site reaction. Almost every patient, in both the GP2+GM-CSF and GM-CSF only arms, reported injection site reactions.

The most frequent injection site reactions were erythema, pruritus and induration, as presented in Table 2. The incidence in AEs was similar across HER2 3+ and HER2 1-2+ patients.

6 Year Performance Since IPO – Planning & Initiation of Phase III Trial in up to 180 sites in 10 Countries



Flamingo-01 Steering Committee

The Steering Committee is comprised of the following members :

- Dr. Mothaffar F. Rimawi – Professor of Medicine at the Baylor College of Medicine
- Dr. Francois-Clement Bidard – Professor of Medical Oncology, UVSQ/Paris Saclay University, Head of Breast Cancer Group, Institut Curie (Unicancer)
- Dr. William J. Gradishar – Professor of Medicine at the Feinberg School of Medicine at Northwestern University
- Dr. Sibylle Loibl – Professor (apl) Goethe University Frankfurt/M, Clinical Consultant Centre for Haematology and Oncology/Bethanien Frankfurt/M (GBG)
- Dr. Miguel Martin – Professor of Medicine, Head, Medical Oncology Service, Gregorio Marañón General University Hospital, Complutense University, Madrid, GEICAM
- Dr. Joyce A. O'Shaughnessy – Celebrating Women Chair in Breast Cancer, Baylor University Medical Center & Chair, Breast Cancer Program, US Oncology/Sarah Cannon
- Dr. Hope S. Rugo – Professor, Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Professor Emeritus, UCSF
- Dr. Laura M. Spring – Assistant Professor, Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital
- Dr. Cesar A. Santa-Maria – Associate Professor of Oncology, Breast and Gynecological Malignancies Group, Director of Breast Cancer Trials, Johns Hopkins SKCCC

Participating networks:	USOncology/Sarah Cannon, TRIO-US, GEICAM (Spain), Unicancer (France), GBG (Germany), GIM (Italy)
Potential additions:	Canada, United Kingdom

Networks
Sarah Cannon/US Oncology
TRIO US

Breast Cancer – *Still* a Substantial Unmet Need

- *Unmet Need is to address the 50% of recurring patients who do not respond to Herceptin or Kadcyla – an opportunity for GP2.*
- *Adjuvant Setting: Following breast cancer surgery, HER2/neu 3+ patients receive Herceptin in the first year and then hope that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years. Herceptin reduces recurrence rates from 25% to 12%.*
- *Neoadjuvant Setting: Kadcyla is approved for use in patients with residual disease, who do not achieve a pCR, as determined at time of surgery. Kadcyla reduces recurrence rates from 22% to 11%.*
- *Neither Perjeta or Nerlynx fully address this unmet need, even in their most efficacious subpopulations.*


GP2 Addresses Unmet Need: GP2 & GM-CSF starting in Year 2 act with minimal to no side effects & no SAEs.

In the initial GP2 indication in the US & EU, ~88k new patients could be treated per year, saving up to 7,000 to 10,000 lives per year.

(12.5% * 700k new pts = 88k pts/yr for all HLAs)




GP2 Phase III Clinical Trial Dosing



- Study allows prior use of pertuzumab, trastuzumab, and ado-trastuzumab emtansine and concurrent neratinib
- Final DTH/immunologic assays at 48 months and at time of recurrence

GP2 Market Positioning & Feedback from KOLs


- As only injection site reactions were observed (which speaks to the immunogenicity of GP2) and with no SAEs attributable to GP2, GP2 can be positioned as the final treatment for patients post surgery
- Patients are seeking a de-escalation and a return to normal life free of toxic treatments, especially if the chance of recurrence is reduced substantially
- GP2 can be the treatment that will naturally overlap with or follow Herceptin, Kadcyla, or Enhertu or any of the other Herceptin derivatives being developed



Synergy with Herceptin Alone **

** 5 Year Disease Free Survival without use of Kadcyca, Perjeta, Nerlynx, Enhertu, or Tukysa

Herceptin Approved for Adjuvant Treatment of HER2/neu 3+ Breast Cancer




Number at risk (N= 3752)

AC→T+H	1872	1529	1240	997	764	575	426	239
AC→T	1880	1490	1159	926	689	534	375	195

AC=doxorubicin/cyclophosphamide T=paclitaxel H=Herceptin

Phase IIb Results for GP2 Target Population, if Fully Immunized (median 5 years follow-up)



Number at risk

GP2	46	46	46	46	46	45	45	45	42	40	30	4	2	1	1	1	0
Placebo	50	50	49	48	47	47	46	46	46	43	33	7	3	2	1	0	0

GP2 Placebo

Joint Analysis Trial

*DFS – Disease Free Survival

ROW strategy: GP2 could eventually be developed with only trastuzumab biosimilar

GP2 Clinical Data:



***GP2 is Immunogenic &
Clinically Effective***



Greenwich
LifeSciences

HER2/*neu* Signaling Pathway Well Studied

- HER2/*neu* pathway activates cancer cell proliferation
- Overexpression of HER2/*neu* correlates strongly with aggressive cancers




GP2 Product Description & Mechanism of Action


- 9 amino acid transmembrane peptide segment of HER2/*neu* protein
- Intradermal injection in combination with an FDA-approved immunoadjuvant GM-CSF, following 1st year of Herceptin treatment in Adjuvant Setting

Leukine®
sargramostim

Herceptin®
trastuzumab



- Given once per month for six months followed by 5 booster doses every 6 months = 11 doses over 3 years
- Mechanism of Action: 4 primary steps, followed by a secondary epitope spreading & broader immune response



Summary of GP2 Completed Trials - N=146 GP2-Treated Patients to Date with No SAEs Attributable to GP2

Study	Design and Control	Product, Dose, and Route	Regimen	Number of Subjects	Population	Duration of Follow-Up
Phase 1b 04-20017, (MCHL-SG (40-38a))	3x3 Dose-escalation	- GP2 at 100, 500, 1000mcg - GM-CSF at 250mcg (reduced to 125mcg in many subjects) - Intradermal	6 doses, every 3-4 weeks	18	- Breast cancer - HER2/neu 1-3+ - HLA-A*02 - Node negative	Primary safety follow-up for the duration of treatment + 30 days.
Phase 1b (C.2008.146)	3x3 Dose-escalation	- GP2+GM-CSF - GP2 at 100, 500, 1,000mcg - GM-CSF at 125, 250mcg - Intradermal - Concurrent iv trastuzumab	6 doses, every 3 weeks	17	- Breast cancer - HER2/neu 1-3+ - HLA-A*02 and HLA-A*03	Primary safety follow-up for the duration of treatment + 30 days.
Phase 1	3x3 Dose-escalation	- GP2+AE37+GM-CSF - GP2 at 100, 250, 500mcg - AE37 at 100, 250, 500mcg - GM-CSF at 125mcg - Intradermal	6 doses, 1 month apart	22	- Breast and ovarian cancer - HER2/neu 1-3+ - HLA-A*02 and HLA-A*03	1.5 years
Phase 2b (C.2007.098)	Randomized, Single-Blind	- GLSI-100 or GM-CSF alone - GP2 500mcg - GM-CSF 125mcg	6 doses, 1 month apart 4 boosters beginning at 12 mo. then every 6 mo.	180 GLSI-100 (n = 89) GM-CSF alone (n = 91)	- Breast cancer - HER2/neu 1-3+ - HLA-A*02 - Node-positive and High-risk node-negative	5 years

GP2 Phase III Trial – FLAMINGO-01:

***Strategy – Conservatively Reproduce
Phase IIb Trial in Larger Population***



**Greenwich
LifeSciences**

Flamingo-01 - Phase III Trial Flamingo-01

- Approximately 180 sites are active
- Flamingo-01 is evaluating the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2/neu positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery
- What is next – transition into pre-commercialization activities:
 - Working with the FDA in preparation for a BLA submission and commercial launch
 - Implementing a global strategy for launching GP2 in international markets outside the US and Europe
 - 1st commercial lot completed - large scale manufacturing, packaging, and marketing
- Additional activities/milestones:
 - Phase III clinical trial progress and open label data is being presented at major conferences – AACR, ASCO
 - Licensing discussions accelerating as the interim analysis approaches
 - Other assets may be developed by acquisition or internal research, including T cell therapies that may be discovered in the Phase III trial by studying GP2's robust immunogenicity
 - Additional patents for GP2 based on the Phase III trial findings, manufacturing, and pharmacy procedures are planned to be filed to extend patent life

Flamingo-01 - Phase III Trial Schema


Phase III Trial Schema

Major Screening Criteria:

- HER2/*neu* 3+ and HLA type
- Residual disease
- pCR if Stage III at presentation

Stratified by:

- Residual disease/pCR
- Hormone receptor status
- Geographic region



Interim Analysis Design

New Interim Design:

- Combining all new patients into one randomized arm independent of HLA type
- More than doubling of enrollment and event rate
- Continuation of enrollment until an event driven interim analysis is conducted and the appropriate size of each arm can be further assessed
- First interim analysis: 28 events, HR = 0.55
- Added second interim analysis
- Regulatory review continues

- Potential for multiple pathways for marketing approval of GLSI-100 and a doubling of market
- Publishing data from open label arm at conferences as data matures

Derisked Phase III Trial

The Phase III clinical trial has been derisked by:

- Increasing the size of the study, which would increase the power of the study thus decreasing the risk by designing the study to assume more recurrences with a higher HR even though fewer recurrences may be anticipated and observed
- By increasing the original FLAMINGO-01 trial design HR = 0.3 to a design HR = 0.55 and by doubling the events required to trigger the first interim analysis from 14 to 28 events, the probability of success or power at the first interim analysis, if a lower study result HR = 0.3 is realized, increases from less than 20% to more than 85%.
- This increase in power at the first interim, when the study result HR is lower than the design HR, is possible due to the combination of both HLA types, while the more than double event rate at 2.22x offsets the doubling of the events required to trigger this first interim analysis.
 - Non-HLA-A*02 patients represent about 55% of the population. Combining all HLAs increases the enrollment rate by 122% ($55\%/45\% = 122\%$), resulting in a 2.22x faster enrollment rate, which proportionately increases the event rate
- Continuing to enroll past the interim analyses so that the current momentum at the clinical sites continues by increasing the size of the study to up to 2,000 patients
 - The first interim results could be achieved with less than 2,000 patients enrolled and the results may affect or alter the design of the second interim
 - Endpoints can be analyzed by individual HLA types as well as one combined group of all HLA types and given that each patient has 2 HLA-A alleles, one from each parent, there are multiple analyses that can be conducted and thus multiple pathways to filing a BLA in the US with much higher probabilities of success at each opportunity for analysis
- Using a recently manufactured GP2 commercial drug product lot in FLAMINGO-01

New Design May Double the Market for GLSI-100

Commercial benefits of combining all non-HLA-A*02 and HLA-A*02 patients into blinded arms:

- The study is now designed and sized to improve the probability of success, to attract the interest of sophisticated investors and pharma companies, and to maximize the chances that the Company could file a BLA after interim analysis 1, after interim analysis 2, or after the end of the study
- The Company plans to now leverage the increased enrollment rate resulting from the combination of all HLA types together with the following:
 - The very high interest from patients and clinicians which has led to approximately 180 clinical trial sites in the US and Europe
 - The currently trending low event rate
 - The efficient cost structure and low burn rate that the Company has successfully funded through small capital raises
 - The Company's annual burn rate was approximately \$7 million in 2024 and 2023 and \$10 million in 2025
 - This capital raising strategy may provide a bridge to non-dilutive funding, such as strategic/licensing partnerships or debt/royalty financing vehicles, that would further fund FLAMINGO-01 and potential commercial launch activities

Doubling the market for GLSI-100 to potentially \$10 billion in revenue per year by accelerating the clinical development of the non-HLA-A*02 population.

FLAMINGO-01 - Hallmarks of a Large Pharma Phase III Trial

Comparison of FLAMINGO-01 to Katherine (Kadcyla) and Destiny Breast-05 (Enhertu):

- By doubling the number of events to trigger an interim and increasing the HR to 0.55, which is offset by the more than doubling event rate due to the higher enrollment rate, and may or may not alter time lines, the probability of a positive study outcome can be increased substantially.
- The Katherine study which compared Kadcyla to Herceptin breast cancer treatment in the adjuvant setting after surgery in the residual disease population assumed a design HR = 0.75 but realized a lower study result HR at the first interim of 0.5, which led to a sufficiently low p value and strong enough statistical significance to warrant approval for Kadcyla in the adjuvant setting following submission of interim data to the FDA. Approximately 1,486 patients were enrolled, 256 events were observed at the interim analysis, and 385 events were observed at the final analysis.
- The Destiny Breast-05 study which compared Enhertu to Kadcyla breast cancer treatment in the adjuvant setting after surgery, in a higher risk residual disease population than Katherine, assumed a design HR = 0.675 but realized a lower study result HR at the first interim of 0.5, which led to a sufficiently low p value and strong enough statistical significance to warrant approval for Enhertu in the adjuvant setting following submission of interim data to the FDA. Approximately 1,635 patients were enrolled and 153 events were observed at the interim analysis.
- GLSI-100 by contrast has shown a study result HR = 0.2 in the Phase IIb clinical trial for HLA-A*02 patients.
 - In the 250 patient non-HLA-A*02 open label arm of FLAMINGO-01, which is now fully enrolled and where all patients received GLSI-100, a Q1 2026 preliminary analysis of recurrence rates after the PIS is completed shows an approximately 70-80% reduction in recurrence rate or a HR = 0.2-0.3 when calculated by various methods.
 - This data is early and will continue to mature over time. This low event rate is supported by immune response data that was recently published at AACR and ASCO conferences in 2026.

Non-HLA-A*02 Open Label Poster at AACR 2026 by Steering Committee



American Association for Cancer Research®, April 17-22, 2026

CT138

Preliminary delayed-type-hypersensitivity immune response results from open-label arm of ongoing Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01

Snehal S. Patel¹, Jaye Thompson¹, F. Joseph Daugherty¹, Francois-Clement Bidard², William J. Gradishar³, Marcus Schmidt⁴, Miguel Martin⁵, Joyce A. O'Shaughnessy⁶, Hope S. Rugo⁷, Cesar A. Santa-Maria⁸, Laura M. Spring⁹, and Mothaffar F. Rimawi¹⁰

¹Greenwich LifeSciences, Stafford, TX, ²Institut Curie, Paris, France, ³Northwestern University, Chicago, IL, ⁴University Medical Center Mainz, Mainz, Germany, ⁵GEICAM, Madrid, Spain, ⁶Sarah Cannon Research Institute, Dallas, TX, ⁷City of Hope Comprehensive Cancer Center, Duarte, CA, ⁸Johns Hopkins University, Baltimore, MD, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX



BACKGROUND

This Phase III trial, FLAMINGO-01, is a prospective, randomized, double-blinded, multi-center study (NCT05232916) in HLA-A*02 patients at approximately 160 sites in the US and Europe. A third non-randomized arm of approximately 250 non-HLA-A*02 patients is now fully enrolled and preliminary immune response data is presented below. GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) that stimulates an immune response targeting HER2/neu expressing cancers, the combination known as GLSI-100.

METHODS

After standard of care neoadjuvant and adjuvant therapy, 6 intradermal injections of GLSI-100 will be administered over the first 6 months and 5 subsequent boosters will be administered over the next 2.5 years. The patient duration of the trial will be 3 years treatment plus 1 additional year follow-up. Immune responses to GP2 were measured over time using delayed-type-hypersensitivity (DTH) skin tests and injection site reactions (ISRs). The patient population is defined by these key eligibility criteria: 1) HER2/neu positive, and HLA-A*02, 2) Residual disease or High risk pCR (Stage III at presentation) post neo-adjuvant therapy, 3) Exclude Stage IV, and 4) Completed at least 90% of planned trastuzumab-based therapy.

Delayed Type Hypersensitivity tests (DTH) were conducted at various times throughout the study. A small amount of GP2 alone, without the adjuvant GM-CSF, is placed under the patient's skin and 48 to 72 hours later, the test site is assessed for evidence of redness or induration.

CONTACT INFORMATION

Flamingo-01@GreenwichLifeSciences.com

Snehal Patel, Greenwich LifeSciences, Stafford, Texas
<https://clinicaltrials.gov/ct2/show/NCT05232916>
[GreenwichLifeSciences.com](https://www.greenwichlifesciences.com)

FLAMINGO TREATMENT




TABLE 1: DTH IMMUNE RESPONSE TO GP2 BY HLA

HLA-A Allele Present ¹	Number of Patients ²	Baseline Reaction (Redness) n (%)	Reaction at Month 4 or 6 (Redness) n (%)	% Increase from Baseline to Month 4 or 6
All non-HLA-A*02 ³	191	10 (5.2)	39 (20.4)	290%
HLA-A*01	65	5 (7.7)	18 (27.7)	280%
HLA-A*03	54	1 (1.9)	8 (14.8)	700%
HLA-A*11	29	2 (6.9)	6 (20.7)	200%
HLA-A*24	52	2 (3.8)	8 (15.4)	300%
HLA-A*29	28	2 (7.1)	4 (14.3)	100%
HLA-A*30	16	3 (18.8)	6 (37.5)	100%
HLA-A*08	25	2 (8.0)	6 (24.0)	200%

¹ Patients with at least one allele. Doublet allele patients are reported once. Patients with 2 different alleles reported twice under each allele.
² Patients with complete paired data (baseline and Month 4 or 6 assessment)
³ Patients without an HLA-A*02 allele treated in open-label arm

FUNDING & CONFLICT OF INTEREST

This trial is supported by Greenwich LifeSciences. Snehal Patel is an employee, owns stock/options, and is a board member of Greenwich LifeSciences.

RESULTS

Patients enrolled in the open-label study (n=247) were vaccinated with GLSI-100 and continue in treatment and follow-up. A DTH reaction (redness and/or induration) was used to assess in vivo immune responses in patients. The DTH orthogonal mean was also measured 48-72 hours after injection but is not reported here.

In this preliminary data analysis, there was a significant increase in percentage of patients experiencing a DTH reaction (redness) in month 4 or month 6 compared to baseline. There were 191 patients with both baseline and month 4 or 6 assessment. The frequency of DTH reactions increased by approximately 4x (290%) in the total open-label non-HLA-A*02 population, increasing from 5.2% of the patients experiencing a DTH reaction at baseline, prior to any GLSI-100 administration, to 20.4% of the patients experiencing a DTH reaction in month 4 or month 6 (McNemar, p < 0.001). As reported in Table 1, each HLA-A type exhibited more frequent immune reactivity after treatment with GLSI-100 than at baseline with frequency increasing from 100% to 700%.

Baseline DTH reaction prior to any treatment suggests that GP2 may be a natural antigen.

Analysis excludes patients in the HLA-A*02 arms, which may have other non-HLA-A*02 alleles.

The study is ongoing and data collection and cleaning continue so final results may vary.

CONCLUSIONS

The increase in the incidence of DTH reactions over time found in this preliminary analysis of GLSI-100 treated non-HLA-A*02 patients shows that GLSI-100 treatment should not be limited to the HLA-A*02 genotype. Subjects treated with GLSI-100 were increasingly able to mount an immune response to GP2 as evidenced in this preliminary data. Future investigations may explore the use of immune responses to assess correlation of DTH to ISRs, immunogenicity of GLSI-100 by specific HLA type, timing of boosters to sustain immunity, clinical site performance, and the discontinuation of treatment for non-responders.

This presentation is the intellectual property of the authors/presenters. Contact them at snehal.patel@greenwichlifesciences.com for permission to reprint and/or distribute.



Greenwich
LifeSciences

Non-HLA-A*02 Open Label Poster at ASCO 2026 by Steering Committee



FLAMINGO-01

American Society of Clinical Oncology®, May 29 – June 2, 2026

Preliminary injection site reaction immune response results from open-label arm of ongoing Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01

Snehal S. Patel¹, Jaye Thompson¹, F. Joseph Daugherty¹, François-Clement Bidard², William J. Gradishar³, Miguel Martín⁴, Joyce A. O'Shaughnessy⁵, Hope S. Rugo⁶, Cesar A. Santa-Maria⁷, Marcus Schmidt⁸, Laura M. Spring⁹, and Mothaffar F. Rimawi¹⁰

¹Greenwich LifeSciences, Stafford, TX, ²Institut Curie, Paris, France, ³Northwestern University, Chicago, IL, ⁴GEICAM, Madrid, Spain, ⁵Sarah Cannon Research Institute, Dallas, TX, ⁶City of Hope Comprehensive Cancer Center, Duarte, CA, ⁷Johns Hopkins University, Baltimore, MD, ⁸University Medical Center Mainz, Mainz, Germany, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX

LBA538

Baylor College of Medicine

DAN L. DUNCAN COMPREHENSIVE CANCER CENTER

BACKGROUND

This Phase III trial, FLAMINGO-01, is a prospective, randomized, double-blinded, multi-center study (NCT05232916) in HLA-A*02 patients at approximately 160 sites in the US and Europe. A third non-randomized arm of approximately 250 non-HLA-A*02 patients is now fully enrolled and preliminary immune response data is presented below.

GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) that stimulates an immune response targeting HER2/neu expressing cancers, the combination known as GLSI-100.

TABLE 1: INJECTION SITE REACTION TO GLSI-100 BY HLA

HLA-A Allele Present ¹	Number of Patients ²	Erythema			Induration		
		Baseline Reaction n (%)	Reaction at Dose 4, 5 or 6 n (%)	% Increase Baseline to Dose 4, 5 or 6	Baseline Reaction n (%)	Reaction at Dose 4, 5 or 6 n (%)	% Increase Baseline to Dose 4, 5 or 6
All non-HLA-A*02s	208	42 (20.2)	115 (55.3)	174%	31 (14.9)	72 (34.6)	132%
HLA-A*01	68	10 (14.7)	38 (55.9)	280%	9 (13.2)	24 (35.3)	167%
HLA-A*03	57	12 (21.1)	30 (52.8)	150%	6 (10.5)	16 (28.1)	167%
HLA-A*11	33	6 (18.2)	19 (57.6)	217%	6 (18.2)	11 (33.3)	83%
HLA-A*24	54	12 (22.2)	30 (55.6)	150%	12 (22.2)	24 (44.4)	100%
HLA-A*29	33	7 (21.2)	18 (54.5)	157%	5 (15.2)	8 (24.2)	60%
HLA-A*30	18	4 (22.2)	9 (50.0)	125%	2 (11.1)	5 (27.8)	150%
HLA-A*68	31	6 (19.4)	20 (64.5)	233%	5 (16.1)	9 (29.0)	80%

¹ Patients with at least one allele. Double allele patients are reported once. Patients with 2 different alleles reported twice under each allele.
² Patients with complete paired data (baseline and Dose 4, 5 or 6 assessment)
³ Patients without an HLA-A*02 allele treated in open-label arm

RESULTS

Patients enrolled in the open-label study (n=247) were vaccinated with GLSI-100 and continue in treatment and follow-up. Injection site reactions, erythema (redness) and induration were assessed at various time points and represent an in vivo immune response in patients. In this preliminary data analysis, there were 208 participants with both baseline and dose 4, 5 or 6 assessment. The study is ongoing and data collection and cleaning continue so final results may vary.

Erythema: There was a significant increase in the percentage of patients experiencing erythema ISRs after the 4th, 5th or 6th vaccination compared to the ISRs from the 1st vaccination.

In this preliminary analysis, the frequency of ISRs increased significantly from 20.2% of the patients experiencing an ISR after the first vaccination to 55.3% of the patients experiencing an ISR after the 4th, 5th or 6th vaccination (McNemar p < 0.001), representing an increase of 2.7x or 174%.

Induration: There was a significant increase in the percentage of patients experiencing induration ISRs after the 4th, 5th or 6th vaccination compared to the ISRs from the 1st vaccination. In this preliminary analysis, the frequency of ISRs increased significantly from 14.9% of the patients experiencing an ISR after the first vaccination to 34.6% of the patients experiencing an ISR after the 4th, 5th or 6th vaccination (McNemar p < 0.001), representing an increase of 2.3x or 132%.

As reported in Table 1, each HLA-A type exhibited more frequent immune reactivity after treatment with GLSI-100 than at baseline, with frequency increasing from 60% to 280%.

METHODS

After standard of care neoadjuvant and adjuvant therapy, 6 intradermal injections of GLSI-100 will be administered over the first 6 months and 5 subsequent boosters will be administered over the next 2.5 years. The patient duration of the trial will be 3 years treatment plus 1 additional year follow-up. Immune responses to GP2 were measured over time using delayed-type hypersensitivity (DTH) skin tests and injection site reactions (ISRs). The patient population is defined by these key eligibility criteria: 1) HER2/neu positive and HLA-A*02, 2) Residual disease or High risk pCR (Stage III at presentation) post neo-adjuvant therapy, 3) Exclude Stage IV, and 4) Completed at least 90% of planned trastuzumab-based therapy.

Injection Site Reactions (ISR) were assessed 48 to 72 hours after vaccination. The site is assessed for evidence of erythema (redness) or induration, including measurements of diameters of both. Each patient presents two alleles and results are reported for both.

CONTACT INFORMATION

Flamingo-01@GreenwichLifeSciences.com

Snehal Patel, Greenwich LifeSciences, Stafford, Texas
<https://clinicaltrials.gov/ct2/show/NCT05232916>
[GreenwichLifeSciences.com](https://www.GreenwichLifeSciences.com)

FUNDING & CONFLICT OF INTEREST

This trial is supported by Greenwich LifeSciences. Snehal Patel is an employee, owns stock/options, and is a board member of Greenwich LifeSciences.

Comparing Non-HLA-A*02 Data to Phase IIb Study

Preliminary Flamingo-01 data available in Q1 2026 is summarized in a blinded manner. This summary may not reflect results at the end of the study.

- 250 patient non-HLA-A*02 arm is now fully enrolled - all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data 50 patients treated in the Phase IIb trial
- Primary Immunization Series (PIS) is first 6 GLSI-100 injections over first 6 months leading to peak protection, followed by 5 booster injections every 6 months providing longer-term protection.
 - Preliminary analysis of recurrence rates after the PIS is completed shows an approximately 70-80% reduction in recurrence rate.
 - This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
 - The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
 - The frequency of DTH reactions increased by approximately 4x (290%) in the total open-label non-HLA-A*02 population, increasing from 5.2% of the patients experiencing a DTH reaction at baseline, prior to any GLSI-100 administration, to 20.4% of the patients experiencing a DTH reaction in month 4 or month 6 (McNemar, $p < 0.001$).
 - Each HLA-A type exhibited more frequent immune reactivity after treatment with GLSI-100 than at baseline with frequency increasing from 100% to 700%.
 - Baseline DTH reaction prior to any treatment suggests that GP2 may be a natural antigen and that GP2 specific T cells may exist in some patients prior to any treatment with GLSI-100, which was also observed in the Phase IIb trial and is being observed in the blinded HLA-A*02 randomized arms of FLAMINGO-01.

Expand by HLA - GP2-HLA Observed & Predicted Prevalence

Preliminary Flamingo-01 data available to date is summarized in a blinded manner. This summary may not reflect results at the end of the study.

- Across all screened patients, HLA-A*02 prevalence is about 46%. The double HLA-A*02 prevalence, in patients who have received HLA-A*02 alleles from both parents, is about 8%. The HLA-A*03, HLA-A*24, and HLA-A*01 prevalences are about 20-25% for each allele. The HLA-A*11, HLA-A*68, HLA-A*29, and HLA-A*30 prevalences are about 9-12% for each allele.
- In those screened patients who self-report race as:
 - White - HLA-A*02 genes are prevalent in 50% of the patients
 - Hispanic or Latino - HLA-A*02 alleles are prevalent in 50% of the patient
 - Black or African-American - HLA-A*02 alleles are prevalent in 40% of the patients
 - Asian - HLA-A*02 alleles are prevalent in 17% of the patients

Frequency of Class I MHC alleles HLA in the North America - Data from HLA Matchmaker

Allele	White	Allele	Black	Allele	Hispanic	Allele	Asian/ Pacific
A*02:01	45.6%	C*04:01	29.0%	A*02:01	37.1%	A*11:01	38.4%
C*07:01	27.7%	C*07:01	25.4%	C*04:01	25.4%	A*24:02	33.7%
A*01:01	27.4%	C*06:02	23.0%	A*24:02	24.9%	C*07:02	33.3%
A*03:01	23.8%	A*02:01	22.3%	C*07:02	24.2%	C*01:02	27.7%
C*07:02	21.5%	A*23:01	20.7%	C*07:01	20.8%	A*33:03	23.3%
C*04:01	21.2%	C*02:02	19.0%	C*03:04	14.4%	C*08:01	21.6%
B*44:02	20.2%	A*03:01	18.7%	A*03:01	14.3%	C*03:04	19.9%
B*07:02	18.1%	C*07:02	18.1%	B*07:02	13.2%	A*02:01	18.1%

GP2 May Address Unmet Need in Both HER2/neu 3+ Adjuvant & Neoadjuvant Settings

Adjuvant

Surgery

ER/PR +
4+ LN

ER/PR –
LN+

Chemotherapy
+ trastuzumab
→ **neratinib**
(2y total)

Chemotherapy
+ trastuzumab
+ **pertuzumab**
(1y total)

Projected 5 Year Recurrence Rates

9-12%

9-12%

Neoadjuvant

ER/PR +
Any LN

ER/PR –
LN+

Chemotherapy
+ trastuzumab

Chemotherapy
+ trastuzumab
+ **pertuzumab**

Surgery

pCR
trastuzumab

*Residual
disease*
TDM1

pCR
trastuzumab

*Residual
disease*
TDM1

5-10%

17%

5-10%

17%

**Conclusion: GP2 should
eventually be pursued in
both settings for all HER2
positive patients**



Target Population for Phase III Trial:

Residual Disease
& High Risk pCR

Annual recurrence rate = 3.0-3.4%

Annual recurrence rate design for Phase III trial = 2.4%

GP2 Specific & Secondary Immune Response TCR Sequencing

Multiple Open Label Immune Response Assessments are Planned to Potentially Identify GP2 Specific T cells, Biomarkers, Booster Strategies, and Early Recurrers

1. Delayed Type Hypersensitive (DTH) skin test for in vivo immune response to GP2 (20% of dose)
2. Injection site reaction measurements which are correlated to DTH in Phase IIb trial
3. Single cell sequencing of T cells resulting from spiked dendritic cells
4. TCR sequencing from frozen blood samples over course of Phase III trial (Example: extensive sequencing of COVID-19 infection & vaccinated patient samples)
5. Potential for ctDNA analysis of plasma
6. Potential for Elispot assay for quantification of functional GP2 specific T cells

GP2 Commercial Opportunity




Greenwich
LifeSciences

Potential Indications of GP2 & Herceptin in Various Populations in Neoadjuvant Setting

- HER2/*neu* 3+ protein over-expression (25%) & 1-2+ expression (50%)


- All breast cancer patients are tested for HER2/*neu* expression by immunohistochemistry (IHC) or fluorescence in situ hybridisation (FISH)



- Node Positive (60%) & High Risk Node Negative (40%)
 - Node positive – cancer has spread to lymph nodes
 - High risk node negative – no cancer in lymph nodes but at high risk for recurrence
 - The more lymph node involvement the more aggressive the cancer
- Hormone Receptor Positive (60%) & Hormone Receptor Negative (40%)

- HLA Type: HLA-A2 (40-50%) & HLA-A3,A24 (30%)

- Human leukocyte antigen (HLA) presents peptide from inside cancer cell to killer T-cells
 - HLA also presents injected peptide to create killer T-cells following intradermal injection



- 12.5% of 700k new US and EU breast cancer patients per year could lead to up to 88k new patients per year for GP2 (12.5% * 700k new pts = 88k pts/yr for all HLA types)
- 12.5% of 9.5m long term US and EU breast cancer survivors could be candidates for GP2 (Sources: American Cancer Society, Economic Impact, & European Cancer Information System 2025)


Commercial Opportunity for GP2 in Breast Cancer in US/EU

- 1 in 8 U.S. women (12.8%) will develop invasive breast cancer over her lifetime, with 317k new breast cancer patients per year in 2025 (400k in EU)
- An estimated 42k female breast cancer deaths will occur in the US in 2025
- GP2's target market is 6-30% of available breast cancer market or up to 2.4x that of Herceptin in adjuvant setting
- GP2 could be a long term treatment that treats survivors (4m as of 2025, 5.5m in EU)
- Herceptin/Perjeta/Nerlynx/Kadcyla pricing from \$75k - \$125k per patient per year
- 11 doses over 3 years in initial indication

	Herceptin	GP2
US & EU Market Potential (Size = 9.5m current breast cancer survivors and 700k new patients per year)		
HER2/ <i>neu</i> Expressors (1-3+)	25% (3+)	25-75% (1-3+)
HLA Type	100%	50-80% (2/3/24/26)
Residual Disease or High Risk pCR	50%	50%
Target Market Potential	12.5%	6.25 - 30%
Theoretical New Patients per Year	35,250	44,000 – 210,000 in US/EU
Adjuvant Patients Treated per Year (est. from sales)	27,000 – 40,000	88k - 420k pts/yr for all HLA types.
Estimated Adjuvant Setting US Revenue (\$ billions)		
Estimated Price (first year)	\$74,500	TBD (6 primary + 1 booster)
Estimated Price (booster)	Not Approved	TBD (4 boosters over 2 years)
Estimated 2017 Global Revenue (\$ billions)		
Adjuvant Setting	\$2-3	US Revenue could double when adding EU market and quadruple when adding all HLA types.
Metastatic Breast Cancer	\$4-5	

Potential Commercial Opportunities / Additional Indications for GP2: HER2/*neu* Expressed in Multiple Cancers

Figure 3. Leading Sites of New Cancer Cases and Deaths – 2021 Estimates



Estimates are rounded to the nearest 10, and cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder. Estimates do not include Puerto Rico or other US territories. Ranking is based on modeled projections and may differ from the most recent observed data.

©2021, American Cancer Society, Inc., Surveillance Research

Denotes cancers where HER2/*neu* over expression has been reported

Veteran Management Team / Board

- David McWilliams, MBA – Chairman, Board
 - 40 years of start-up / CEO experience
 - CEO of 2 private and 3 public biotech companies
- Snehal Patel, MS, MBA – CEO, Board
 - 30 years of biopharma / Wall Street experience
 - Large pharma operations / management experience
- Joe Daugherty, M.D. – CMO, Board
 - 35 years of biopharma experience
 - Assisted over 20 public and private companies
- Jaye Thompson, Ph.D. – VP Clinical & Regulatory
 - 30 years of active involvement in over 200 clinical trials for drugs, biologics and devices
 - Founder of multiple CROs
- Christine Fischette, Ph.D. – VP Business Development
 - 30 years of big pharma R&D & commercialization
 - Business development / multiple licensing transactions
- Eric Rothe – Board & Founder of GLSI
- Ken Hallock – Board & Major Investor



McKinsey&Company



ENCYSIVE™
PHARMACEUTICALS



OPEXA THERAPEUTICS



Bayer

JPMorganChase



Massachusetts
Institute of
Technology



General Electric



INTROGEN
Therapeutics, Inc.

Manufacturing / Regulatory / IP

- GP2 manufactured by straightforward amino acid chemistry
 - Manufactured by FDA-approved commercial facility with multiple back-up facilities
 - Commercial manufacturing commenced
 - 3 clinical lots followed by 3 commercial lots
 - GM-CSF is commercially available, along with Saline/WFI, which will all be sold independently
- Discussing potency assay / HLA companion diagnostic
- GP2 registered as biologic with CBER – 12 years exclusivity in US
- GP2 issued patents provide protection through 2032 in the major markets (US, EU, Canada, Australia, & Japan), including ongoing prosecution in emerging markets - patent term extensions possible
- New patent applications




Recently granted Fast Track designation by FDA

GLSI Strategy is to Conduct Additional GP2 Trials

Greenwich's current strategy is as follows:

- **Reproduce** Phase IIb trial in Phase III trial in HER2 positive patients only – no material changes to treatment regimen, upgrade immune response assays, expand to multiple HLA types
- **Optimize** GP2 treatment by starting treatment in neoadjuvant setting in another Phase II/III trial and utilize immune response data, if possible, to “optimize” timing of inoculations
- **Expand** to HER2 low breast cancer and other HER2 expressing cancers using optimized treatment methods and add checkpoint inhibitors



ROE of developing GP2 could be high!

GP2 Conclusions: A Breakthrough Targeted Immunotherapy for Prevention of HER2/*neu* Cancer



Flamingo-01 - Current Phase III Trial with Interim Analysis: 9 amino acid HER2/*neu* peptide + GM-CSF immunotherapy for breast cancer in HER2/*neu* positive patients following neoadjuvant, surgery, & adjuvant Herceptin or Kadcyla, led by Baylor & consortium of prominent networks - up to 180 sites in US & EU

- Conservative design of Phase III trial to reproduce Phase IIb results
- Phase IIb Trial Results: Randomized, multi-center (16 centers), placebo-controlled, substantial reduction in recurrence rate, peak immunity after 6 months, minimal to no side effects, no SAEs attributable to GP2, led by MD Anderson Cancer Center
- Potential Opportunities to Expand Market:
 - HER2/*neu* low patients with Herceptin - increase market from 25% to 75%
 - ✓ – Other HLA types – increase from 40-50% up to 80-100% of all patients
 - Combination with CD4/CD8 peptides and checkpoints
 - Other HER2/*neu* cancers
- NASDAQ Ticker “GLSI”: Raised \$60m since IPO

Recently granted Fast Track designation by FDA



GLSI Sponsorship of 5k Race in Houston each October



Research

that provides new hope through lifesaving discoveries. Funding breakthroughs that give more time to everyone in their fight against breast cancer.



Care

that ensures all have access to quality screening, diagnosis and treatment for breast cancer. Offering patient support, treatment assistance, even childcare and transportation services.



Community

to support everyone, no matter where they are in their breast cancer journey. Providing a safe place to share, grieve, support and find strength forward.



Action

through advocacy, fighting for government funding and critical patient support and research. We fight for the rights of patients among policymakers and compassionate care for everyone.





**Greenwich
LifeSciences**
NASDAQ: GLSI

For Additional Information, Please Contact:

Snehal Patel
CEO

Telephone: 832.819.3232

E-mail: info@greenwichlifesciences.com

Website: greenwichlifesciences.com

© 2026 GLSI